Monday, September 26, 2016

Starlix


Starlix is a brand name of nateglinide, approved by the FDA in the following formulation(s):


STARLIX (nateglinide - tablet; oral)



  • Manufacturer: NOVARTIS

    Approval date: December 22, 2000

    Strength(s): 120MG [RLD][AB], 60MG [AB]

Has a generic version of Starlix been approved?


A generic version of Starlix has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Starlix and have been approved by the FDA:


nateglinide tablet; oral



  • Manufacturer: DR REDDYS LABS LTD

    Approval date: September 9, 2009

    Strength(s): 120MG [AB], 60MG [AB]


  • Manufacturer: PAR PHARM

    Approval date: September 9, 2009

    Strength(s): 120MG [AB], 60MG [AB]


  • Manufacturer: TEVA PHARMS

    Approval date: September 9, 2009

    Strength(s): 120MG [AB], 60MG [AB]


  • Manufacturer: WATSON LABS

    Approval date: March 30, 2011

    Strength(s): 120MG [AB], 60MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Starlix. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
    Patent 5,463,116
    Issued: October 31, 1995
    Inventor(s): Sumikawa; Michito & Koguchi; Yoshihito & Ohgane; Takao & Irie; Yasuo & Takahashi; Satoji
    Assignee(s): Ajinomoto Co., Inc.
    Stable crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine may be produced by treating this compound with a solvent at a temperature of at least 10.degree. C. and forming crystals in the solvent at a temperature of at least 10.degree. C. For example, crystals may be formed by crystallization out of solution, or may be formed from solid particles of the compound suspended in a solvent. Crystals formed in this way have different melting point, infra red spectrum and X-ray diffraction patterns from previously known forms of the compound and have enhanced processability, e.g., stability to grinding.
    Patent expiration dates:

    • October 21, 2012




  • Crystals of N-(trans-4-isopropylcyclohexycarbonyl)-D-phenylalanine and methods for preparing them
    Patent 5,488,150
    Issued: January 30, 1996
    Inventor(s): Sumikawa; Michito & Koguchi; Yoshihito & Ohgane; Takao & Irie; Yasuo & Takahashi; Satoji
    Assignee(s): Ajinomoto Co., Inc.
    Stable crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine may be produced by treating this compound with a solvent at a temperature of at least 10.degree. C. and forming crystals in the solvent at a temperature of at least 10.degree. C. For example, crystals may be formed by crystallization out of solution, or may be formed from solid particles of the compound suspended in a solvent. Crystals formed in this way have different melting point, infra red spectrum and X-ray diffraction patterns from previously known forms of the compound and have enhanced processability, eg. stability to grinding.
    Patent expiration dates:

    • January 30, 2013




  • Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
    Patent 6,559,188
    Issued: May 6, 2003
    Inventor(s): Marjorie Regan; Gatlin & Michele Ann; Ball & Richard Owen; Mannion & Anees Abdulquadar; Karnachi & Christiane; Guitard & Malcolm; Allison
    Assignee(s): Novartis AG
    The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises nateglinide (I) or repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and metformin for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases and conditions associated with diabetes; to a composition, respectively, which comprises nateglinide and a pharmaceutically acceptable carrier and to a process of making such composition; the use of such combination or composition for the preparation of a medicament for the prevention, delay of progression or treatment of metabolic disorders; a method of prevention, delay of progression or treatment of diseases in warm-blooded animals; the use of such combination or composition for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight; and to a method of improving the bodily appearance of a warm-blooded animal.
    Patent expiration dates:

    • September 15, 2020
      ✓ 
      Patent use: USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES
      ✓ 
      Drug product




  • Tablet composition
    Patent 6,641,841
    Issued: November 4, 2003
    Inventor(s): Akira; Yabuki & Masato; Kaida & Takahiko; Ando & Nobutaka; Ninomiya & Masanao; Ozaki
    Assignee(s): Ajinomoto Co., Inc.
    A tablet composition containing N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine and low substituted hydroxypropylcellulose is disclosed. This tablet composition is rapidly disintegrated in the stomach after the administration and absorbed without being influenced by meals to inhibit the rise of the blood sugar levels of diabetics after meals.
    Patent expiration dates:

    • November 14, 2017
      ✓ 
      Patent use: USE AS A BLOOD GLUCOSE-LOWERING AGENT
      ✓ 
      Drug product




  • Tablet composition
    Patent 6,844,008
    Issued: January 18, 2005
    Inventor(s): Yabuki; Akira & Kaida; Masato & Ando; Takahiko & Ninomiya; Nobutaka & Ozaki; Masanao
    Assignee(s): Ajinomoto Co., Inc.
    A tablet composition containing N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine and a disintegrant, selected from a low substituted hydroxypropylcellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose and sodium croscaramellose sodium, is disclosed. This tablet composition is rapidly disintegrated in the stomach after the administration and absorbed without being influenced by meals to inhibit the rise of the blood sugar levels of diabetics after meals.
    Patent expiration dates:

    • November 14, 2017
      ✓ 
      Patent use: USE AS A BLOOD GLUCOSE-LOWERING AGENT
      ✓ 
      Drug product




  • Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
    Patent 6,878,749
    Issued: April 12, 2005
    Inventor(s): Gatlin; Marjorie Regan & Ball; Michele Ann & Mannion; Richard Owen & Karnachi; Anees Abdulquadar & Guitard; Christiane & Allison; Malcolm
    Assignee(s): Novartis AG
    The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises nateglinide (1) stet or repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and metformin for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases and conditions associated with diabetes; to a composition, respectively, which comprises nateglinide and a pharmaceutically acceptable carrier and to a process of making such composition; the use of such combination or composition for the preparation of a medicament for the prevention, delay of progression or treatment of metabolic disorders; a method of prevention, delay of progression or treatment of diseases in warm-blooded animals; the use of such combination or composition for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight; and to a method of improving the bodily appearance of a warm-blooded animal.
    Patent expiration dates:

    • September 15, 2020
      ✓ 
      Drug product



See also...

  • Starlix Consumer Information (Drugs.com)
  • Starlix Consumer Information (Wolters Kluwer)
  • Starlix Consumer Information (Cerner Multum)
  • Starlix Advanced Consumer Information (Micromedex)
  • Starlix AHFS DI Monographs (ASHP)
  • Nateglinide Consumer Information (Wolters Kluwer)
  • Nateglinide Consumer Information (Cerner Multum)
  • Nateglinide Advanced Consumer Information (Micromedex)
  • Nateglinide AHFS DI Monographs (ASHP)
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)